In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...
Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...
The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...
Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...
The study was conducted between August 2019 and October 2021 across 15 centers in Iran. It involved adult patients with RMS who met specific inclusion criteria. Participants were randomly assigned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback